CancerDrs

Lung Cancer clinical trials in Kentucky

35 actively recruiting lung cancer trials at 11 sites across Kentucky.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Kentucky:
  • Norton Cancer Institute Downtown — Louisville, Kentucky
  • Norton Cancer Institute, Downtown — Louisville, Kentucky
  • Norton Hospital — Louisville, Kentucky
  • Norton Audubon Hospital — Louisville, Kentucky
  • Norton Cancer Institute, Audubon Hospital Campus — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Kentucky:
  • Research Site — Lexington, Kentucky
  • Research Site — Lexington, Kentucky
  • Research Site — Louisville, Kentucky
  • Research Site — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Kentucky:
  • Owensboro Health Mitchell Memorial Cancer Center — Owensboro, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Kentucky:
  • Research Site — Paducah, Kentucky
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Kentucky:
  • Baptist Health Hardin — Elizabethtown, Kentucky
  • Baptist Health Lexington — Lexington, Kentucky
  • University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center) — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Kentucky:
  • Saint Elizabeth Medical Center Edgewood — Edgewood, Kentucky
  • The University of Louisville, James Graham Brown Cancer Center — Louisville, Kentucky
  • Owensboro Medical Health System — Owensboro, Kentucky
  • Mercy Health-Paducah Medical Oncology and Hematology — Paducah, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Kentucky:
  • Research Site — Lexington, Kentucky
  • Research Site — Owensboro, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …

Sponsor: AbbVie
NCT ID: NCT07365241
Sites in Kentucky:
  • Baptist Health Louisville /ID# 280025 — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…

Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in Kentucky:
  • Norton Cancer Institute, Downtown — Louisville, Kentucky
  • Pikeville Medical Center — Pikeville, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Kentucky:
  • Baptist Health Corbin — Corbin, Kentucky
  • Baptist Health Lexington — Lexington, Kentucky
  • Baptist Health Hamburg — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Kentucky:
  • Norton Cancer Institute — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naï…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165070
Sites in Kentucky:
  • University of Kentucky Markey Cancer Center ( Site 0019) — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …

Sponsor: AbbVie
NCT ID: NCT07155174
Sites in Kentucky:
  • Baptist Health Lexington /ID# 277729 — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Federal

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Participants will receive either a combinati…

Sponsor: VA Office of Research and Development
NCT ID: NCT06681220
Sites in Kentucky:
  • Robley Rex VA Medical Center, Louisville, KY — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT07169734
Sites in Kentucky:
  • Norton Cancer Institute - Norton Healthcare Pavilion — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in Kentucky:
  • Norton Cancer Institue Downtown — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immun…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06731907
Sites in Kentucky:
  • University of Kentucky ( Site 0019) — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)

Sponsor: Haihe Biopharma Co., Ltd.
NCT ID: NCT04270591
Sites in Kentucky:
  • Norton Cancer Institute — Louisville, Kentucky
  • The Oncology Institute of Hope & Innovation — Louisville, Kentucky
View on ClinicalTrials.gov →

Showing 25 of 35 trials with sites in Kentucky. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01